Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onartuzumab plus erlotinib versus placebo plus erlotinib in first-line MET-positive EGFR-mutant advanced NSCLC
2013-000868-29Phase 3Terminated
- Sponsor
- Roche
- Start
- Jul 2013
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Onartuzumab + erlotinib with Placebo + erlotinib (2 arms). Primary endpoint: Progression-free survival. Started Jul 2013; status: terminated.
02
Drugs
onartuzumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2013-000868-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000868-29.